Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. develops plant-derived prescription medicines for gastrointestinal disease states in people and animals. Its human-health news centers on crofelemer, including Mytesi for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and rare-disease intestinal failure programs tied to microvillus inclusion disease and short bowel syndrome through Napo Pharmaceuticals and Napo Therapeutics.
Company updates also cover animal-health products such as conditionally approved Canalevia-CA1 for chemotherapy-induced diarrhea in dogs and the Neonorm franchise for gut health in animals. Recurring corporate news includes Nasdaq listing-compliance matters, reverse stock splits, warrant exercises, stockholder meetings, proxy proposals, and other capital-structure actions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Jaguar Health (Nasdaq:JAGX) announced that enrollment in its pivotal Phase 3 OnTarget clinical trial of crofelemer has surpassed 90%, with completion expected by mid-Q2 2023. This trial aims to assess the effectiveness of crofelemer in preventing diarrhea in adult cancer patients undergoing targeted therapy. The company’s current cash position stands at approximately $15.3 million. The OnTarget trial, now expanded to include sites in Eastern Europe, Argentina, and Taiwan, is crucial in demonstrating that chronic diarrhea affects patient adherence to cancer therapies. The trial evaluates crofelemer’s unique mechanism of action, targeting chloride ion channels in the gastrointestinal tract.
Jaguar Health (NASDAQ:JAGX) announced on April 6, 2023, its ongoing efforts to identify potential illegal naked short selling activities affecting its stock. The company has engaged Shareholder Intelligence Services to uncover trading anomalies and ensure compliance with FINRA and SEC regulations. Preliminary findings have shown slight trade imbalances meriting further investigation. Jaguar aims to safeguard shareholder interests and enhance shareholder value through this initiative.
ShareIntel's proprietary platform identifies markers of illegal short selling, assisting companies in ensuring true price discovery. Jaguar intends to keep the market updated on any material findings from this ongoing analysis.
Jaguar Health, Inc. (JAGX) announced its participation at the Veterinary Cancer Society Collaborative Conference from April 19-22, 2023, promoting Canalevia-CA1, the first FDA conditionally approved treatment for chemotherapy-induced diarrhea (CID) in dogs. As of December 2022, the FDA expanded the annual treatment capacity from 70,000 to 80,000 dogs, enhancing the market potential for Canalevia-CA1. The drug is available through major U.S. veterinary distributors, reflecting an ongoing commitment to address significant unmet needs among veterinarians treating cancer patients.
Jaguar Health reported a substantial growth in prescription product net revenue, totaling $11.9 million for the year ending December 31, 2022, marking a 178.7% increase from $4.3 million in 2021. The fourth quarter of 2022 alone saw revenues of approximately $3.3 million, up 3.4% from the previous quarter. As of March 24, 2023, the company had a cash position of $15.3 million. Key initiatives include progressing through 80% enrollment in the Phase 3 OnTarget trial for crofelemer aimed at cancer therapy-related diarrhea, and plans for additional investigator-initiated studies in 2023. The investor webcast on March 27 will further detail these updates.
Jaguar Health, Inc. (NASDAQ:JAGX) has announced a change in the timing of its investor webcast, now scheduled for March 27, 2023 at 8:00 AM EDT, to discuss the fourth-quarter 2022 financial results and corporate updates. The company plans to file its Annual Report on March 24, 2023, for the fiscal year ended December 31, 2022. Jaguar focuses on developing plant-based prescription medications for gastrointestinal distress in humans and animals. Its subsidiary, Napo Pharmaceuticals, is conducting a pivotal Phase 3 trial for the drug crofelemer aimed at cancer patients experiencing diarrhea.